X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs SUN PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD SUN PHARMA BIOCON LTD/
SUN PHARMA
 
P/E (TTM) x 75.5 25.1 301.0% View Chart
P/BV x 7.1 3.7 193.9% View Chart
Dividend Yield % 0.2 0.6 27.8%  

Financials

 BIOCON LTD   SUN PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
SUN PHARMA
Mar-17
BIOCON LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162842 138.0%   
Low Rs483572 84.3%   
Sales per share (Unadj.) Rs194.6131.6 147.8%  
Earnings per share (Unadj.) Rs34.432.7 105.2%  
Cash flow per share (Unadj.) Rs48.338.0 127.1%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.10.5 24.6%  
Book value per share (Unadj.) Rs241.9152.7 158.4%  
Shares outstanding (eoy) m200.002,399.26 8.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.25.4 78.6%   
Avg P/E ratio x23.921.6 110.5%  
P/CF ratio (eoy) x17.018.6 91.5%  
Price / Book Value ratio x3.44.6 73.4%  
Dividend payout %2.910.7 27.2%   
Avg Mkt Cap Rs m164,4401,696,877 9.7%   
No. of employees `0009.217.5 52.7%   
Total wages/salary Rs m7,47049,023 15.2%   
Avg. sales/employee Rs Th4,213.918,028.3 23.4%   
Avg. wages/employee Rs Th809.02,798.8 28.9%   
Avg. net profit/employee Rs Th745.24,479.5 16.6%   
INCOME DATA
Net Sales Rs m38,911315,784 12.3%  
Other income Rs m1,5716,232 25.2%   
Total revenues Rs m40,482322,016 12.6%   
Gross profit Rs m9,795100,893 9.7%  
Depreciation Rs m2,77212,648 21.9%   
Interest Rs m2603,998 6.5%   
Profit before tax Rs m8,33490,479 9.2%   
Minority Interest Rs m1630-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,61612,116 13.3%   
Profit after tax Rs m6,88178,462 8.8%  
Gross profit margin %25.231.9 78.8%  
Effective tax rate %19.413.4 144.8%   
Net profit margin %17.724.8 71.2%  
BALANCE SHEET DATA
Current assets Rs m40,477329,537 12.3%   
Current liabilities Rs m16,783178,870 9.4%   
Net working cap to sales %60.947.7 127.6%  
Current ratio x2.41.8 130.9%  
Inventory Days Days6079 75.5%  
Debtors Days Days8383 99.5%  
Net fixed assets Rs m45,073204,766 22.0%   
Share capital Rs m1,0002,399 41.7%   
"Free" reserves Rs m47,377363,997 13.0%   
Net worth Rs m48,377366,397 13.2%   
Long term debt Rs m21,08214,361 146.8%   
Total assets Rs m93,942614,102 15.3%  
Interest coverage x33.123.6 139.9%   
Debt to equity ratio x0.40 1,111.8%  
Sales to assets ratio x0.40.5 80.5%   
Return on assets %7.613.4 56.6%  
Return on equity %14.221.4 66.4%  
Return on capital %12.624.8 50.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98844,118 29.4%   
Fx outflow Rs m7,89924,484 32.3%   
Net fx Rs m5,08919,634 25.9%   
CASH FLOW
From Operations Rs m6,40070,822 9.0%  
From Investments Rs m-4,985-42,216 11.8%  
From Financial Activity Rs m-1,775-22,854 7.8%  
Net Cashflow Rs m-4736,107 -7.7%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS